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Life cycleMacrophages and CD4+ lymphocytes are the major reservoirs for HIV-1 infection. CD63 is a tetraspanin
transmembrane protein, which has been shown to play an essential role during HIV-1 replication in
macrophages. In this study, we further conﬁrm the requirement of CD63 in early HIV-1 replication events in
both macrophages and a CD4+ cell line. Further analysis revealed that viral attachment and cell–cell fusion
were unaffected by CD63 silencing. However, CD63-depleted macrophages showed a signiﬁcant decrease in
the initiation and completion of HIV-1 reverse transcription, affecting subsequent events of the HIV-1 life
cycle. Integration of HIV-1 cDNA as well as the formation of 2-LTR circles was notably reduced. Reporter
assays showed that CD63 down regulation reduced production of the early HIV protein Tat. In agreement,
CD63 silencing also inhibited production of the late protein p24. These ﬁndings suggest that CD63 plays an
early post-entry role prior to or at the reverse transcription step.).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Macrophages and CD4+ T lymphocytes are major target cells for
HIV-1 infection and replication, and play critical roles in multiple
aspects of viral pathogenesis. Numerous host determinants have been
identiﬁed that facilitate HIV-1 replication by performing the essential
steps of the viral life cycle from viral entry to egress (Bergamaschi and
Pancino, 2010). A recent large-scale siRNA screen revealed over 250
host factors that participate in a broad array of cellular functions and
implicate new pathways in the HIV life cycle (Brass et al., 2008). HIV
encodes only 15 proteins and thus must take advantage of multiple
host cell functions for productive infection (Brass et al., 2008). HIV
uses a CD4 receptor (Klatzmann et al., 1984), as well as CCR5 and
CXCR4 co-receptors (Feng et al., 1996; Dragic et al., 1996) for entry
into the host cells. Upon membrane fusion, the viral core containing
the viral nucleocapsid along with HIV RNA, reverse transcriptase,
integrase, protease, and viral accessory proteins is released into the
cytoplasm. Uncoating involves viral proteins as well as a variety of
host factors that promote dissociation of the matrix protein from the
plasma membrane (Aiken, 2006). After uncoating, reverse transcrip-
tase converts viral RNA into DNA which is then transported across the
nucleus and integrates into host chromosome. HIV genes are
transcribed using host enzymes, and viral mRNA is transported
outside the nucleus, and is used as a blueprint for producing new HIV
proteins and enzymes. Some studies have reported reverse transcrip-tion to be largely associated with cellular enzymes or cofactors in vitro
(Hooker and Harrich, 2003; Warrilow et al., 2008, 2010). HIV
integration and proviral transcription also require the use of host
cell factors (Goodarzi et al., 1999; Greene, 1991). Following viral gene
expression, the cellular GTPase Rab9 facilitates trafﬁcking of viral
proteins from the late endosome to the trans-Golgi (Murray et al.,
2005). HIV assembly and release utilizes TSG101 and the Endosomal
Sorting Complexes Required for Transport (ESCRTs), a network of
cellular factors that sort proteins and facilitate HIV budding (von
Schwedler et al., 2003; Morita and Sundquist, 2004).
Historically, all antiretroviral treatments targeted viral proteins.
More recently, however, FDA-approved Maraviroc® (Selzentry) and
Aplaviroc® (GlaxoSmithKline) are the ﬁrst antiretroviral drugs that
target a cellular gene CCR5 co-receptor, and have been demonstrated
to be effective and shown to cause less resistance among HIV
phenotypes than previous generations of drugs (Reeves and Piefer,
2005; Hughes et al., 2008). Like CCR5, CD63 is another cellular protein
that may represent an important new therapeutic target for the
development of antiretroviral drugs.
CD63 is a type II cellular membrane protein and belongs to the
tetraspanin superfamily (Stipp et al., 2003; Hemler, 2005). It has been
reported that CD63 incorporates into HIV-1 virions (Chertova et al.,
2006; Pelchen-Matthews et al., 2003; Sato et al., 2008) and colocalizes
with HIV-1 Env and Gag proteins in HIV-1 producing cells (Raposo et
al., 2002; Pelchen-Matthews et al., 2003; Grigorov et al., 2006; Jolly
and Sattentau, 2007; Perlman and Resh, 2006). In addition, CD63 has
been shown to be associated with tetraspanin-enriched mircrodo-
mains (TEMs) that act as the gateway for HIV-1 budding at the plasma
membrane (Nydegger et al., 2006).
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infection events in macrophages and a CD4+ cell line. Our earlier
studies showed that anti-CD63monoclonal antibody treatment 30 min
prior to and during infection markedly reduced HIV replication in
macrophages (von Lindern et al., 2003). Inhibitionwas shown to occur
during early infection, suggestive of involvement in virus entry or
reverse transcription. Our more recent studies conﬁrm the require-
ment of CD63 in HIV-1 replication by pretreatment with CD63-speciﬁc
siRNA in bothmacrophages and a CD4+ cell line (Chen et al., 2008). In
this study, we investigated the role of CD63 during sequential steps of
the HIV-1 replication cycle including viral attachment, cell–cell fusion,
reverse transcription, integration, and early and late viral protein
expression in both human monocyte-derived macrophages (MDMs)
and CD4+ U373-MAGI-CCR5 cells. These studies revealed that CD63-
depleted macrophages showed a signiﬁcant decrease in the initiation
and completion of HIV-1 reverse transcription, affecting subsequent
events of the HIV-1 life cycle. However, events prior to reverse
transcription including viral attachment and cell–cell fusion were not
affected. These ﬁndings further support a role for CD63 in an early,
post-entry event of the HIV-1 replication cycle, particularly prior to or
at the reverse transcription step.
Results
CD63 mRNA down regulation by siRNA in human MDMs and
U373-MAGI-CCR5 cells
To conﬁrm the down regulation of CD63 by siRNA in MDMs and
U373-MAGI-CCR5 cells, mRNA was extracted and analyzed by
quantitative reverse transcriptase PCR (qRT-PCR). CD63 mRNAFig. 1. Conﬁrmation of CD63 mRNA down regulation via real-time PCR.(A) MDMs (5×105 ce
and transfected with 50 nM siRNAs (CD63, CD4, and ERBB2IP). For controls, cells were treate
infected with HIV-1 SX (m.o.i.=0.02) only. Total mRNA was isolated from each well using th
relative CD63 expression levels, normalizing to GAPDH expression as an internal control.expression was silenced by N90% or N95% following CD63 siRNA
transfections of MDMs and U373-MAGI-CCR5 cells, respectively
(Figs. 1A and B). CD63 mRNA was not signiﬁcantly reduced by
transfections of other siRNAs (CD4, ERBB2IP) or FDA approved HIV-1
inhibitors (AZT, RT inhibitor; Raltegravir, and integrase inhibitor) used
throughout this study indicating speciﬁcity for CD63 siRNA down
regulation in both MDMs and U373-MAGI-CCR5 cells. ERBB2IP siRNA
was used as a cellular target negative control, as our previous studies
showed that silencing ERBB2IP does not inhibit HIV-1 (Murray et al.,
2005). Western blot analysis revealed that CD63 protein expression
was signiﬁcantly reduced in CD63-siRNA transfectants compared to
the cells transfectedwith control siRNAs or non-transfected cells (data
not shown), consistent with our previous ﬁndings (Chen et al., 2008).
CD63 down regulation affects HIV-1 production in human MDMs and
U373-MAGI-CCR5 cells
To gauge the effect of CD63 down regulation on viral production,
MDMs and U373-MAGI-CCR5 cells were transfected with various
speciﬁc siRNAs or ERBB2IP control siRNA, or were treated with the
integrase inhibitor raltegravir, followed by HIV-1 SX infection 48 h
post-transfection. HIV-1 SX virus production was assessed in culture
supernatants by p24 ELISA at 7 days post-infection of MDMs (Fig. 2A)
or at 5 days post-infection of U373-MAGI-CCR5 cells (Fig. 2B). As
shown in Figs. 2A and B, virus production in both cell types was
signiﬁcantly reduced following CD63 or CD4 silencing, or raltegravir
treatment compared to ERBB2IP siRNA transfected cells. (Pb0.05).
Similar results were also observed in MDMs lysates (Fig. 2C), where
intracellular HIV-1 SX p24 production was dramatically reduced by
silencing CD63, to the same extent as the CD4 siRNA control group.lls/well) or (B) U373-MAGI-CCR5 cells (1×105 cells/well) were plated in 24-well plates
d with AZT (1 μM) or raltegravir (20 mM). Controls also included untreated cells or cells
e Qiagen RNeasy kit 48 h after transfection. Quantitative RT-PCR was used to determine
Fig. 2. Effects of CD63 silencing on HIV-1 replication in human MDMs and U373-MAGI-CCR5 cells.(A) MDMs (5×105 cells/well) or (B) U373-MAGI-CCR5 cells (1×105 cells/well)
were plated in triplicate in 24-well plates and transfected with 50 nM siRNAs (CD63, CD4, and ERBB2IP). Controls included cells treated with raltegravir (20 mM), untreated cells or
cells treated with virus infection only. Forty eight hours post-transfection, cells were infected with HIV-1 SX (m.o.i.=0.02). Supernatants were harvested for p24 detection on day 5
post-infection for U373-MAGI-CCR5 cells, and on day 7 post-infection for MDMs using p24 Capture ELISA kit (ImmunoDiagnostics, Woburn, MA). (C) Cell lysates fromMDMs on day
7 post-infection were also harvested for detection of intracellular p24. *Pb0.05, **Pb0.01, compared with ERBB2IP control group, respectively.
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Because CD63 silencing affects HIV-1 replication, we looked
systematically at the effect of CD63 inhibition at successive stages
within the HIV-1 replication cycle. Since antibody-mediated neutrali-
zation of HIV-1 has been shown to inhibit virus-receptor binding, and
interferewith events after binding (Ugolini et al., 1997),we investigated
the effect of CD63onHIV-1 attachment byvirus-cell binding assay using
anti-CD63. Herewe showed solublemonoclonal antibodies to CD63 and
control monoclonal antibody CD82 did not inhibit the adsorption of
HIV-1 SX to MDMs (Fig. 3), however, soluble CD4monoclonal antibody
showed dramatic inhibition of virus binding compared to those of anti-
CD63, anti-CD82 and virus only (Pb0.01). In contrast, the anti-CD63
antibody showed no inhibition of HIV-1 binding to MDMs, suggesting
that CD63 has no effect on viral attachment of MDMs.CD63 has no effect on cell–cell fusion
Since CD63 is not required for virus attachment (Fig. 3), the
subsequent step after binding in the HIV life cycle is to assess virus
entry. We therefore tested any potential role for CD63 in virus entry
using cell–cell fusion assay by co-culturing HL2/3 cells, which express
Tat and HIV receptor Env proteins gp41 and gp120, with U373-MAGI-
CCR5 cells. HIV Env proteins on HL2/3 cells interact with primary
receptor CD4 and co-receptor CCR5 on U373-MAGI-CCR5 cells,
prompting cellular fusion via the same mechanism used by HIV;
upon fusion, Tat activates β-gal expression. Decreased CD63 levels had
no effect on β-gal activity, whereas decreased CD4 and CCR5 levels
correlatedwith diminishedβ-gal activity, consistentwith inhibition of
viral fusion inhibitor drug T-20 (Fig. 4). Together, these data suggest
that CD63 has no effect on viral entry of U373-MAGI-CCR5 cells.
Fig. 3. Anti-CD63 does not inhibit HIV-1 attachment to human MDMs.MDMs (1×103 cells/well) were pretreated for 30 min at 37 °C with Iscove's modiﬁed Dulbecco's medium
(IMDM) alone, 25 μg/ml of anti-CD63 antibody (Invitrogen), 25 μg/ml of anti-CD82 antibody (Invitrogen), or 25 μg/ml of anti-CD4 antibody (BD Sciences) as a positive inhibition
control. Thereafter, HIV-1 SX (m.o.i.=0.02) was added, and incubated for 1 h at 4 °C, and unbound virions were removed by washing with cold PBS containing 1% FBS. The cells were
trypsinized, and the amount of cell-associated p24 in trypsin was determined with p24 Capture ELISA kit. Controls included cells treated with trypsin only and untreated (no Ab)
cells. Experiments were performed in triplicate. **Pb0.01, compared with anti-CD82 group.
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MDMs and U373-MAGI-CCR5 cells
In order to clarify whether CD63may be required for HIV-1 reverse
transcription, small non-genomic DNA was isolated from control- and
CD63 siRNA-transfected MDMs or U373-MAGI-CCR5 cells at 24 h
post-infection with HIV-1 SX for quantiﬁcation by real time PCR. As
shown in Figs. 5A and C, CD63 silencing affected formation of full
length HIV-1 cDNA, which decreased by approximately 55% in CD63-
deﬁcient MDMs and 75% in CD63-deﬁcient U373-MAGI-CCR5 cells,
compared to those transfected with control siRNA ERBB2IP or
untransfected cells (Pb0.05). In addition, we measured the formation
of strong stop DNA, which is the ﬁrst piece of DNA (147 bp)
synthesized during the initiation of reverse transcription. HIV strong
stop DNA formation (Figs. 5B and D) decreased by approximately 65%
in CD63-deﬁcient MDMs and 80% in CD63-deﬁcient U373-MAGI-CCR5
cells, compared to those transfected with ERBB2IP or virus infection
only (Pb0.01). Inhibition of strong stop DNA formation is consistent
with our earlier studies, in which MDMs were pretreated with anti-
CD63, followed by HIV-1 infection (von Lindern et al., 2003). Full
length viral DNA formation was not detected in cells treated with the
reverse transcription inhibitor AZT (Figs. 5A and C), whereas viralFig. 4. CD63 silencing has no effect on cell–cell fusion.U373-MAGI-CCR5 target cells (104 cell
For controls, fusion inhibitor T20 (1 μg/ml or 10 μg/ml) was used as well as fusion only condi
cells were co-cultured with 2×104 of HL2/3 effector cells per well at 37 °C for 12 h to allow fu
activation stimulated by HIV-1 Tat from the HL2/3 cells. All experiments were performed istrong stop formation was evident in cells treated with AZT (Figs. 5B
and D). As expected, AZT does not inhibit strong stop formation, only
full length HIV DNA (Arts and Wainberg, 1994). Collectively, these
data indicate that CD63 serves a critical post-entry role early in the
HIV life cycle either before or during reverse transcription strong stop
DNA formation, at a step upstream of AZT. Sequential steps following
reverse transcription in the HIV life cycle were assessed to determine
if steps downstream of reverse transcription were impaired by CD63
silencing.Decreased integration of HIV-1 cDNA in both CD63 deﬁcient human
MDMs and U373-MAGI-CCR5 cells
To address the effects of CD63 for proviral DNA integration, genomic
DNA was isolated from cells post-infected with HIV-1 SX. Quantitative
real-time PCR was used to quantify differences in HIV-1 SX integration
between control cells (ERBB2IP- or CD4-siRNA transfectants; AZT
and raltegravir treated cells; virus infection only or cell only) and
CD63-siRNA transfected cells. Down regulation of CD63 resulted in
signiﬁcantly reduced amounts of integrated HIV-1 cDNA in both
MDMs (Fig. 6A) and U373-MAGI-CCR5 cells (Fig. 6B) (Pb0.01).s/well) were transfected with CD63-, CD4-, or CCR5-speciﬁc siRNAs and ERBB2IP siRNA.
tions containing no siRNA. Forty-eight hours post-transfection U373-MAGI-CCR5 target
sion to occur. Fusion was monitored by assaying for Tat-dependent β-gal reporter gene
n quadruplicate.*Pb0.05, **Pb0.01, compared with ERBB2IP group.
Fig. 5. CD63 silencing reduces HIV-1 reverse transcription in humanMDMs and U373-MAGI-CCR5 cells.The effect of HIV-1 reverse transcription on the formation of full length cDNA
(A and C) and the initiation of strong stop (B and D)were performed inMDMs (5×105 cells/well) and in U373-MAGI-CCR5 cells (1×105cells/well) that were transfected with 50 nM
siRNAs (CD63 and ERBB2IP). Forty-eight hours post-transfection, cells were infected with HIV-1 SX (m.o.i.=0.02). For controls, cells were treated with reverse transcriptase
inhibitor AZT (1 μM); cells infected with virus only; and untreated cells. Small non-genomic DNA was isolated from controls and CD63 siRNA-transfected MDMs and U373-MAGI-
CCR5 cells at 24 h post-infection. Primers M667/M661, along with probe MH603, was used to quantify full-length cDNA formation (A and C), and primers M667/AA55, along with
probe MH603 was used to quantify strong stop cDNA formation (B and D) by real time PCR. *Pb0.05, compared with ERBB2IP group.
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Fig. 6. CD63 silencing decreases HIV-1 integration and 2-LTR circle formation in human MDMs and U373-MAGI-CCR5 cells(A) MDMs (5×105 cells/well) or (B) U373-MAGI-CCR5
cells (1×105 cells/well) were plated in 24-well plates and transfected with 50 nM siRNAs (CD63, CD4, and ERBB2IP). Controls include cells treated with raltegravir (20 mM) 24 h
prior to infection, during infection and 48 h post- infection and untreated cells. Forty-eight hours post-transfection, cells were infected with HIV-1 SX (m.o.i.=0.02). Genomic DNA
was isolated from cells 5 days (MDMs) and 3 days (U373-MAGI-CCR5 cells) post-infection. Quantitative real-time PCR was used to quantify differences in HIV-1 SX integration
between control cells and CD63-siRNA transfected cells using primers Alu-gag-LTR, and LTR probe (O'Doherty et al., 2002; Friedrich et al., 2010). Plasmid DNAwas isolated from cells
(C) 5 days (MDMs) and (D) 3 days (U373-MAGI-CCR5 cells) post HIV-1 SX infection. Quantitative real-time PCR was used to quantify differences between control cells and CD63-
siRNA transfected cells using primers MH535/MH536 with probe MH603 to detect HIV 2-LTR circle formation (Butler et al., 2001; Friedrich et al., 2010). All experiments were
performed in triplicate. *Pb0.05, **Pb0.01, compared with ERBB2IP group.
320 G. Li et al. / Virology 412 (2011) 315–324
321G. Li et al. / Virology 412 (2011) 315–324CD63 down regulation does not induce HIV-1 2-LTR circle formation
To determine if CD63 expression is necessary immediately prior
to viral integration, small non-genomic DNA was isolated from CD63-
deﬁcient cells after infection to quantify formation of 2-LTR circles.
The cDNA circularizes to form 2-LTR circles if it does not integrate
into the cellular genome (Bukrinsky et al., 1993; Farnet and
Haseltine, 1991), and these 2-LTR circles can be quantiﬁed using
real-time PCR. As shown in Fig. 6, down regulation of CD63 did not
induce 2-LTR circle formation in either MDMs (Fig. 6C) or U373 cells
(Fig. 6D). As expected, 2-LTR circles were dramatically formed in the
cells treated with the integrase inhibitor raltegravir. These results
strongly suggest that CD63 affects the HIV-1 replication cycle
preceding integration.
Inhibition of HIV-1 Tat activity following CD63 down regulation
To determine if CD63 plays a role in early HIV-1 protein
production, U373-MAGI-CCR5 cells were used in a β-galactosidase
reporter gene assay to gauge the effect of CD63 silencing on Tat
function. The LTR-HIV promoter controls expression of β-galactosi-
dase induced by production of HIV Tat. U373-MAGI-CCR5 cells were
transfected with various speciﬁc siRNAs or control siRNA, or were
treated with raltegravir, followed by HIV-1 SX infection 48 h after
transfection. Cells were cultured for 72 h, lysed, and then exposed to a
luminescent β-gal substrate, and expressed as relative light units
(RLU) (Fig. 7). In agreement, we also observed that Tat activity was
dramatically inhibited to background levels in CD63 siRNA-transfec-
tant to the same extent as siRNA speciﬁc for CD4 when compared to
ERBB2IP control siRNA-transfectant or cells exposed to virus infection
only (Pb0.01). These data strongly indicate that CD63 supports HIV-1
replication at a step prior to gene expression.
Discussion
Extensive studies have revealed that HIV-1 exploits multiple host
proteins during infection (Bergamaschi and Pancino, 2010; Brass et
al., 2008; Kumar et al., 2008; Bouazzaoui et al., 2006; Hamamoto et al.,
2006; Stremlau et al., 2004; Krishnan and Zeichner, 2004). These
proteins participate in a broad array of cellular functions and
implicate different pathways in the viral life cycle. However, the
mechanisms by which these proteins play relevant roles in HIV-1
pathogenesis are subjects of continued exploration.Fig. 7. CD63 silencing decreases early HIV-1 protein Tat activity in U373-MAGI-CCR5 cells
and transfected with 50 nM siRNAs (CD63, CD4, and ERBB2IP). Controls included cells trea
Forty eight hours post-transfection, cells were infected with HIV-1 SX (m.o.i.=0.02). Cell
was analyzed using the Beta-Glo Assay System (Promega, Madison, WI), and was detect
group, respectively.In this study, we revealed the role of CD63 during sequential
steps of the HIV-1 replication cycle which include viral attachment,
viral entry (cell–cell fusion), reverse transcription, integration,
early/late viral protein formation, and virion release from infected
human MDMs and U373-MAGI-CCR5 cells. We found that CD63 was
required for efﬁcient HIV-1 reverse transcription and subsequent
steps from integration to egress. However, entry mechanisms
including cell membrane docking and cell–cell fusion life cycle
steps that precede HIV-1 reverse transcription were unaffected. In
all cases, the down regulation of CD63 via speciﬁc siRNA
signiﬁcantly reduced HIV-1 replication in both cell types, suggest-
ing that CD63 is associated with a common mechanism in early
events of the HIV-1 life cycle, speciﬁcally at a step preceding or at
reverse transcription. Since our observation is an early post-entry
step, it is possible that HIV-1 may be linked to an intracellular
signaling event involving CD63. CD63 has been shown to induce
signaling through tyrosine-dependent interaction of its carboxy-
terminal cytoplasmic tail with the AP-3 adaptor subunit (Rous et al.,
2002). In addition, when HIV-1 gp120 binds to CD4 and CCR5 on the
surface of Jurkat T-cells, it has been shown to induce phosphory-
lation of receptor tyrosine kinases such as p56Lck, which in turn
activates the Raf/MEK/ERK and PIP3 kinase pathways and intracel-
lular calcium channels (Popik and Pitha, 1996), implying that an
intracellular signaling route is likely to be important for the HIV-1
life cycle. However, it is not clear how HIV-1 is linked to CD63
signaling, which still remains to be explored.
Although recent studies (Ruiz-Mateos et al., 2008; Krementsov et
al., 2009) showed that CD63 expression is not required for either the
production or the infectivity of HIV-1, numerous studies have
reported that CD63 incorporates into HIV-1 virions and have the
potential to interfere with viral infection (Chertova et al., 2006;
Pelchen-Matthews et al., 2003; Sato et al., 2008; Raposo et al., 2002;
Grigorov et al., 2006; Jolly and Sattentau, 2007; Perlman and Resh,
2006; Nydegger et al., 2006). Our previous studies (von Lindern et al.,
2003; Chen et al., 2008) demonstrated that CD63 plays an important
supportive role in HIV-1 replication in macrophages. Although
controversial data have been published in the last few years
concerning effects of CD63 on HIV-1 replication in macrophages and
other cell types, it is possible that this effect may be dependent on the
cell type, viral strain, and virus concentration. Even though MDMs
display a great heterogeneity in their capacities to replicate HIV-1,
depending on the donors (up to a 3 log difference in viral production)
(Bol et al., 2009; Eisert et al., 2001; Chang et al., 1996), we performed
experiments in macrophages from several different donors as well aU373-MAGI-CCR5 cells (1×105 cells/well) were plated in triplicate in 24-well plates
ted with raltegravir (20 mM), untreated cells or cells treated with virus infection only.
lysates were collected on day 3 post-infection, and Tat-driven β-galactosidase activity
ed by Dynex MLX Luminometer. *Pb0.05, **Pb0.01, compared with ERBB2IP control
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consistently present similar outcomes.
Understanding the virus–host interactions that lead to limited HIV
replication in these cell types can be a powerful tool to identify
molecular mechanisms of innate/intrinsic restriction of HIV replica-
tion. A key pharmacological strategy for treating individuals living
with HIV has been to simultaneously target multiple virus-encoded
enzymes required for replication to overcome emergence of drug
resistance. Our laboratory has pursued an alternate strategy by
identifying host factors, such as CD63, that are required for HIV-1
replication, as HIV-1 should be less likely to evolve resistance to drugs
targeting cellular proteins.
In conclusion, we have revealed that CD63 plays an essential role
in an early, post-entry event of the HIV-1 replication cycle,
particularly prior to or at the reverse transcription step. Whether
CD63 interacts directly with HIV or indirectly, by altering host
dependent factors potentially required for reverse transcription,
remains to be determined. In addition, a recent study (Lin et al.,
2008) showed that expression of CD63 activates protein tyrosine
kinase (PTK) and enhances the PTK-induced inhibition of ROMK
channels. Thus, the role of CD63 in affecting the HIV-1 replication
cycle induced by the stimulation of the PTK pathway is unknown and
further research is needed to gain insight into the molecular signaling
mechanisms, including CD63, PTK and viral proteins that possibly
facilitate early events in the HIV replication cycle.Materials and methods
Cells and culture conditions
U373-MAGI-CCR5 cells (obtained from NIH AIDS Research and
Reference Reagent Program, and contributed by Drs. Michael
Emerman and Adam Geballe), are a cell line derived from a
glioblastoma that has been modiﬁed by stable transfection of LTR-β-
galactosidase which is transactivated by HIV Tat protein during virus
replication (Harrington and Geballe, 1993; Vodicka et al., 1997).
U373-MAGI-CCR5 cells express CD4 and human chemokine receptor
CCR5 on the cell surface, which allow infection by HIV R5 strains
(Vodicka et al., 1997). U373-MAGI-CCR5 cells were propagated in
Dulbecco's modiﬁed Eagle's (DMEM) (Gibco, CA) supplemented with
10% fetal bovine serum (Hyclone, IL), 0.2 mg/ml G418, 0.1 mg/ml
hygromycin B, and 1.0 μg/ml puromycin. For infection experiments,
U373-MAGI-CCR5 cells were maintained in 90% DMEM, 10% fetal
bovine serum, and 1% penicillin/streptomycin (Sigma, MO).
HL2/3 cells (NIH AIDS Research and Reference Reagent Program,
kindly contributed by Dr. Barbara K. Felber and Dr. George N. Pavlakis)
were generated by cotransfection of HeLa cells with the plasmids
pHXB2/3gpt, pSV2neo and selected in geneticin (G418). HL2/3 cells
were selected on the basis of high-level production of Gag, Env, Tat,
Rev, and Nef proteins. Co-cultivation with the CD4 producing cell line
results in efﬁcient cell fusionwithin 6–12 h. Human embryonic kidney
(HEK) 293 T cells were purchased from Invitrogen. Both HL2/3 cells
and 293 T cells were maintained in DMEM supplemented with 10%
fetal bovine serum, 1% non-essential amino acids (Sigma) and 1%
penicillin/streptomycin.
MDMs were puriﬁed from healthy human PBMCs by adherence to
plastic tissue culture dishes as described previously (O'Brien et al.,
1990). Brieﬂy, PBMCs were puriﬁed by Ficoll–Hypaque centrifugation
from buffy coats of healthy HIV-negative blood donors prepared by
the UTMB Blood Bank (Galveston, TX). MDMs were obtained by
adherence for 6 days to plastic Petri dishes initially coated with
human AB serum (Rich et al., 1992). During differentiation, macro-
phages were cultured in Iscove's modiﬁed Dulbecco's medium
(IMDM) supplemented with 20% FCS; 1% L-glutamine and 1%
penicillin/streptomycin.Viruses
HIV-1 SX, which is a chimeric R5-tropic virus encoding the
majority of the HIV-1 JRFL envelope protein in an HIV-1NL4-3
backbone, were purchased from the Virology Core Facility, Center
for AIDS Research at Baylor College of Medicine, Houston, TX. In all
experiments, MDMs and U373-MAGI-CCR5 cells were infected with
HIV-1 SX (m.o.i.=0.02).
siRNA transfections and infectivity assay
The CD63- and CD4-speciﬁc target siRNAs were designed and
synthesized by Dharmacon (Lafayette, CO), ERBB2IP non-HIV speciﬁc
siRNA served as a negative control in each experiment. The target
sequences for siGENOME SMARTpool siRNA of CD63 includes
D-017256 (01-GAGAUAAGGUGAUGUCAGA; 02-AAGGAGAACUAUU-
GUCUUA; 03-GGAUUAAUUUCAACGAGAA; 04-GAUGGAGAAUUACCC-
GAAA). The target sequences for siGENOME SMARTpool siRNA of CD4
includes D-005234 (01-GAACUGACCUGUACAGCUU; 02-AAUCAGGG-
CUCCUUCUUAA; 03-GAAGAAGAGCAUACAAUUC; 18-AUUACCAA-
GUGCCGGACUA); the target sequences for siGENOME SMARTpool
siRNA of ERBB2IP includes D-031861 (01-UGAAACAGCUCA-
CAUAUUU; 02-UGUGAAAUCUCAUAGCAUA; 03-CGAAGAGC-
CAAAUAUAAUA; 04-CCAAACGACCGACUUAUUC) . s iRNA
transfections were performed using oligofectamine (Invitrogen, CA)
following the manufacturer's instructions. In brief, MDMs adherent
for 5 days were plated in 24-well plates (5×105 cells/well), and
transfected with 50 nM siRNAs using oligofectamine in serum-free
Opti-MEM I medium (Gibco) 24 h after plating. Cells were maintained
in Iscove's medium and 20% FCS after 4 h to terminate transfection. In
order to measure down regulation of target genes, cells were lysed by
cell lysis buffer (Promega, WI) and lysates were collected for Western
blot analysis, or RNA was extracted for real time quantitative PCR
analysis at 2 days post-transfection. U373-MAGI-CCR5 cells were
transfected in 24-well plates (1×105 cells/well), using oligofectamine
and 50 nM siRNAs (ﬁnal concentration in supernatants). Subsequent-
ly, cells were fed with DMEM with 10% FCS after 4 h to terminate
transfection, followed by detection of proteins or target gene down
regulation as described earlier.
Forty eight hours post-transfection, MDMs or U373-MAGI-CCR5
cells were infected with HIV-1 SX (m.o.i.=0.02). Culture super-
natants or cell lysates were harvested for p24 detection on day 5 post-
infection in U373-MAGI-CCR5 cells, and on day 7 post-infection
in MDMs using p24 Capture ELISA kit (ImmunoDiagnostics,
Woburn, MA).
In order to assess Tat protein expression, U373-MAGI-CCR5 cells
were lysed on day 3 post-infection, and analyzed for β-galactosidase
activity using the Beta-Glo Assay System (Promega) and a DynexMLX
Luminometer.
Virion attachment assay
The virion attachment assay was performed as previously
described (Tanaka et al., 2003). Brieﬂy, infections are performed in
96-well microtiter plates at a m.o.i. of 0.02. MDMs (103/well) were
pretreated for 30 min at 37 °C with medium only (no antibody),
25 μg/ml of anti-CD63 monoclonal antibody (Invitrogen, clone CLB-
gran/12 CLB-180), 25 μg/ml of anti-CD82 monoclonal antibody
(Invitrogen, clone C-16), or 25 μg/ml anti-CD4 monoclonal antibody
(BD Sciences, clone L200) as a positive inhibition control. Thereafter,
HIV-1 SX was added, which was continued in the presence of
antibody, and incubated for 1 h at 4 °C, and unbound virions were
removed by washing with ice-cold PBS containing 1% FBS. For each
condition, the cells were treated with 0.05% trypsin (Gibco) to cleave
bound virus, and then the amount of cell-associated p24 in the trypsin
was determined with p24 Capture ELISA kit.
323G. Li et al. / Virology 412 (2011) 315–324Cell–cell fusion assay
U373-MAGI-CCR5 target cells, were plated in 96-well plates
(104 cells/well) and cultured overnight, followed by transfection of
CD63-, CD4-, CCR5-speciﬁc siRNAs and ERBB2IP control siRNA. The
medium was removed 48 h post-transfection and 2×104 HL2/3 HeLa
cells were added to each well in fresh medium. HL2/3 HeLa cells
express Tat and HIV envelope proteins gp41 and gp120 that allow
them to efﬁciently interact with CD4 and CCR5 on U373-MAGI-CCR5
target cells, prompting cellular fusion via the same mechanism used
by HIV. The co-culture was incubated at 37 °C for 12 h to allow fusion
to occur; the fusion of U373-MAGI-CCR5 target cells and HL2/3 HeLa
cells was monitored by assaying for Tat-dependent β-gal reporter
gene activation stimulated by HIV-1 Tat from the HL2/3 HeLa cells.
U373-MAGI-CCR5 and HL2/3 cells alone were used to determine
background luminescence. To study the effect of each siRNAs on cell–
cell fusion, fusion inhibitor, T-20, was used as positive control. The
target cells were pre-treated with T-20 (10 μg/ml or 1 μg/ml) for 24 h
followed by incubation with HL2/3 cells in the continued presence of
the T-20. Subsequently, fusion was measured via luminometry
expressed as β-galactosidase production.
Real time quantitative PCR
Primers and probes for real time PCR were custom ordered from
Sigma-Aldrich. Full genomic DNA was isolated from MDMs or cell
lines using the Qiagen Blood and Tissue Kit (Qiagen, Inc., CA). Small
non-genomic DNA, such as reverse transcribed viral cDNA and 2-LTR
circles were isolated using a Qiagen Miniprep kit. To detect strong
stop of reverse transcription, primers M667 and AA55, along with
probe MH603 (Butler et al., 2001) were used; to detect full length HIV
DNA, primers M667 and M661 (Zack et al., 1990), along with probe
MH603 were used; to identify 2-LTR circle formation, as described in
our previous study (Friedrich et al., 2010), primers MH535 and
MH536 were used with the MH603 probe (Butler et al., 2001). Total
mRNA was isolated from siRNA-transfected cells and MDMs using
RNeasy Mini Kits (Qiagen). For integration, a two-step PCR reaction
was performed. For the initial PCR ampliﬁcation, Alu forward and HIV-
1 gag reverse primers were used (O'Doherty et al., 2002; Friedrich et
al., 2010). The second step real-time PCR used the primers LTR
forward, LTR reverse, and LTR probe (O'Doherty et al., 2002; Friedrich
et al., 2010). CD63 speciﬁc primers and probe were purchased from
Applied Biosytems (Carlsbad, CA). All reactions were performed using
Applied Biosystems TaqMan Universal Master Mix and run using an
Applied Biosystems 7500 Fast Real Time PCR system and 7500 Fast
System Software. Silencing of target genes was determined by
normalizing target gene expression to GAPDH expression (n=3).
Statistical analysis
The results are expressed as mean±SD of at least four wells. Two-
tailed, paired Student's t-test was used to determine statistical
signiﬁcance. P values ofb0.05*, andb0.01**were considered signiﬁcant.
Acknowledgments
This work was supported by Public Health Service grant HL088999
from the National Heart, Lung, and Blood Institute. We thank the NIH
AIDS Research and Reference Reagent Program for providing the
U373-MAGI-CCR5 cells. We thank Edward Siwak, Ph.D., Associate
Director of Virology Core Facility, Center for AIDS Research at Baylor
College of Medicine, Houston, TX for providing HIV-1SX. Also, we
greatly appreciate Merck & CO., Inc. for generously providing
raltegravir used in our studies, as well as Drs. Mark A. Endsley and
William A. O'Brien for their excellent editorial suggestions.
We conﬁrm that we have no competing ﬁnancial interests.References
Aiken, C., 2006. Viral and cellular factors that regulate HIV-1 uncoating. Curr. Opin. HIV
AIDS 1, 194–199.
Arts, E.J., Wainberg, M.A., 1994. Preferential incorporation of nucleoside analogs after
template switching during human immunodeﬁciency virus reverse transcription.
Antimicrob. Agents Chemother. 38 (5), 1008–1016.
Bergamaschi, A., Pancino, G., 2010. Host hindrance to HIV-1 replication in monocytes
and macrophages. Retrovirology 7, 31.
Bol, S.M., van Remmerden, Y., Sietzema, J.G., Kootstra, N.A., Schuitemaker, H., van't
Wout, A.B., 2009. Donor variation in in vitro HIV-1 susceptibility of monocyte-
derived macrophages. Virology 390, 205–211.
Bouazzaoui, A., Kreutz, M., Eisert, V., Dinauer, N., Heinzelmann, A., Hallenberger, S.,
Strayle, J., Walker, R., Rubsamen-Waigmann, H., Andreesen, R., von Briesen, H.,
2006. Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in
human monocyte-derived macrophages. Virology 356, 79–94.
Brass, A.L., Dykxhoorn, D.M., Benita, Y., Yan, N., Engelman, A., Xavier, R.J., Lieberman, J.,
Elledge, S.J., 2008. Identiﬁcation of host proteins required for HIV infection through
a functional genomic screen. Science 319 (5865), 921–926.
Bukrinsky, M., Sharova, N., Stevenson, M., 1993. Human immunodeﬁciency virus type 1
2-LTR circles reside in a nucleoprotein complex which is different from the
preintegration complex. J. Virol. 67, 6863–6865.
Butler, S.L., Hansen, M.S., Bushman, F.D., 2001. A quantitative assay for HIV DNA
integration in vivo. Nat. Med. 7, 631–634.
Chang, J., Naif, H.M., Li, S., Sullivan, J.S., Randle, C.M., Cunningham, A.L., 1996. Twin
studies demonstrate a host cell genetic effect on productive human immunode-
ﬁciency virus infection of human monocytes and macrophages in vitro. J. Virol. 70,
7792–7803.
Chen, H., Dziuba, N., Friedrich, B., von Lindern, J., Murray, J.L., Rojo, D.R., Hodge, T.W.,
O'Brien, W.A., Ferguson, M.R., 2008. A critical role for CD63 in HIV replication and
infection of macrophages and cell lines. Virology 379 (2), 191–196.
Chertova, E., Chertov, O., Coren, L.V., Roser, J.D., Trubey, C.M., Bess Jr., J.W., Sowder II, R.C.,
Barsov, E., Hood, B.L., Fisher, R.J., Nagashima, K., Conrads, T.P., Veenstra, T.D., Lifson, J.D.,
Ott, D.E., 2006. Proteomic and biochemical analysis of puriﬁed human immunode-
ﬁciency virus type 1 produced from infected monocyte-derived macrophages. J. Virol.
80 (18), 9039–9052.
Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Nagashima, K.A., Cayanan, C.,
Maddon, P.J., Koup, R.A., Moore, J.P., Paxton,W.A., 1996. HIV-1 entry into CD4+ cells
is mediated by the chemokine receptor CC-CKR-5. Nature 381 (6584), 667–673.
Eisert, V., Kreutz, M., Becker, K., Königs, C., Alex, U., Rübsamen-Waigmann, H.,
Andreesen, R., von Briesen, H., 2001. Analysis of cellular factors inﬂuencing the
replication of human immunodeﬁciency virus type I in human macrophages
derived from blood of different healthy donors. Virology 286, 31–44.
Farnet, C.M., Haseltine, W.A., 1991. Circularization of human immunodeﬁciency virus
type 1 DNA in vitro. J. Virol. 65, 6942–6952.
Feng, Y., Broder, C.C., Kennedy, P.E., Berger, E.A., 1996. HIV-1 entry cofactor: functional
cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272
(5263), 872–877.
Friedrich, B., Li, G., Dziuba, N., Ferguson, M.R., 2010. Quantitative PCR used to assess
HIV-1 integration and 2-LTR circle formation in human macrophages, peripheral
blood lymphocytes and a CD4+ cell line. Virol. J. 7, 354.
Goodarzi, G., Pursley,M., Felock, P.,Witmer, M., Hazuda, D., Brackmann, K., Grandgenett,
D., 1999. Efﬁciency and ﬁdelity of full-site integration reactions using recombinant
simian immunodeﬁciency virus integrase. J. Virol. 73 (10), 8104–8111.
Greene, W.C., 1991. The molecular biology of human immunodeﬁciency virus type 1
infection. N. Engl. J. Med. 324 (5), 308–317.
Grigorov, B., Arcanger, F., Roingeard, P., Darlix, J.L., Muriaux, D., 2006. Assembly of
infectious HIV-1 in human epithelial and T-lymphoblastic cell lines. J. Mol. Biol. 359
(4), 848–862.
Hamamoto, S., Nishitsuji, H., Amagasa, T., Kannagi, M., Masuda, T., 2006. Identiﬁcation
of a novel human immunodeﬁciency virus type 1 integrase interactor, Gemin2, that
facilitates efﬁcient viral cDNA synthesis in vivo. J. Virol. 80 (12), 5670–5677.
Harrington, R.D., Geballe, A.P., 1993. Cofactor requirement for human immunodeﬁ-
ciency virus type 1 entry into a CD4-expressing human cell line. J. Virol. 67,
5939–5947.
Hemler, M.E., 2005. Tetraspanin functions and associated microdomains. Nat. Rev. Mol.
Cell Biol. 6, 801–811.
Hooker, C.W., Harrich, D., 2003. The ﬁrst strand transfer reaction of HIV-1 reverse
transcription is more efﬁcient in infected cells than in cell-free natural endogenous
reverse transcription reactions. J. Clin. Virol. 26 (2), 229–238.
Hughes, A., Barber, T., Nelson, M., 2008. New treatment options for HIV salvage
patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and
CCR5 antagonists. J. Infect. 57 (1), 1–10.
Jolly, C., Sattentau, Q.J., 2007. Human immunodeﬁciency virus type 1 assembly,
budding, and cell–cell spread in T cells take place in tetraspanin-enriched plasma
membrane domains. J. Virol. 81 (15), 7873–7884.
Klatzmann, D., Champagne, E., Chamaret, S., Gruest, J., Guetard, D., Hercend, T.,
Gluckman, J.C., Montagnier, L., 1984. T-lymphocyte T4 molecule behaves as the
receptor for human retrovirus LAV. Nature 312 (5996), 767–768.
Krementsov, D.N., Weng, J., Labele, M., Roy, N.H., Thali, M., 2009. Tetraspanins regulate
cell-to-cell transmission of HIV-1. Retrovirology 6, 64.
Krishnan, V., Zeichner, S.L., 2004. Alterations in the expression of DEAD-box and other
RNA binding proteins during HIV-1 replication. Retrovirology 1, 42.
Kumar, A., Zloza, A., Moon, R.T., Watts, J., Tenorio, A.R., Al-Harthi, L., 2008. Active beta-
catenin signaling is an inhibitory pathway for human immunodeﬁciency virus
replication in peripheral blood mononuclear cells. J. Virol. 82 (6), 2813–2820.
324 G. Li et al. / Virology 412 (2011) 315–324Lin, D., Kamsteeg, E.J., Zhang, Y., Jin, Y., Sterling, H., Yue, P., Roos, M., Dufﬁeld, A.,
Spencer, J., Caplan, M., Wang, W.H., 2008. Expression of tetraspan protein CD63
activates protein-tyrosine kinase (PTK) and enhances the PTK-induced inhibition
of ROMK channels. J. Biol. Chem. 283 (12), 7674–7681.
Morita, E., Sundquist, W.I., 2004. Retrovirus budding. Annu. Rev. Cell Dev. Biol. 20,
395–425.
Murray, J.L., Mavrakis, M., McDonald, N.J., Yilla, M., Sheng, J., Bellini, W.J., Zhao, L., Le
Doux, J.M., Shaw, M.W., Luo, C.C., Lippincott-Schwartz, J., Sanchez, A., Rubin, D.H.,
Hodge, T.W., 2005. Rab9 GTPase is required for replication of human immunode-
ﬁciency virus type 1, ﬁloviruses, and measles virus. J. Virol. 79 (18), 11742–11751.
Nydegger, S., Khurana, S., Krementsov, D.N., Foti, M., Thali, M., 2006. Mapping of
tetraspanin-enriched microdomains that can function as gateways for HIV-1. J. Cell
Biol. 173 (5), 795–807.
O'Brien,W.A., Koyanagi, Y., Namazie, A., Zhao, J.Q., Diagne, A., Idler, K., Zack, J.A., Chen, I.S.,
1990. HIV-1 tropism for mononuclear phagocytes can be determined by regions of
gp120 outside the CD4-binding domain. Nature 348, 69–73.
O'Doherty, U., Swiggard, W.J., Jeyakumar, D., McGain, D., Malim, M.H., 2002. A sensitive,
quantitative assay for human immunodeﬁciency virus type 1 integration. J. Virol.
76, 10942–10950.
Pelchen-Matthews, A., Kramer, B., Marsh, M., 2003. Infectious HIV-1 assembles in late
endosomes in primary macrophages. J. Cell Biol. 162 (3), 443–455.
Perlman, M., Resh, M.D., 2006. Identiﬁcation of an intracellular trafﬁcking and assembly
pathway for HIV-1 gag. Trafﬁc 7 (6), 731–745.
Popik, W., Pitha, P.M., 1996. Binding of human immunodeﬁciency virus type 1 to CD4
induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent
pathway. Mol. Cell. Biol. 16, 6532–6541.
Raposo, G., Moore, M., Innes, D., Leijendekker, R., Leigh-Brown, A., Benaroch, P., Geuze,
H., 2002. Human macrophages accumulate HIV-1 particles in MHC II compart-
ments. Trafﬁc 3 (10), 718–729.
Reeves, J.D., Piefer, A.J., 2005. Emerging drug targets for antiretroviral therapy. Drugs 65
(13), 1747–1766.
Rich, E.A., Chen, I.S., Zack, J.A., Leonard, M.L., O'Brien, W.A., 1992. Increased
susceptibility of differentiated mononuclear phagocytes to productive infection
with human immunodeﬁciency virus-1 (HIV-1). J. Clin. Invest. 89, 176–183.
Rous, B.A., Reaves, B.J., Ihrke, G., Briggs, J.A., Gray, S.R., Stephens, D.J., Banting, G., Luzio,
J.P., 2002. Role of adaptor complex AP-3 in targeting wild-type and mutated CD63
to lysosomes. Mol. Biol. Cell 13 (3), 1071–1082.Ruiz-Mateos, E., Pelchen-Matthews, A., Deneka, M., Marsh, M., 2008. CD63 is not
required for production of infectious human immunodeﬁciency virus type 1 in
human macrophages. J. Virol. 82 (10), 4751–4761.
Sato, K., Aoki, J., Misawa, N., Daikoku, E., Sano, K., Tanaka, Y., Koyanagi, Y., 2008.
Modulation of human immunodeﬁciency virus type 1 infectivity through
incorporation of tetraspanin proteins. J. Virol. 82 (2), 1021–1033.
Stipp, C.S., Kolesnikova, T.V., Hemler, M.E., 2003. Functional domains in tetraspanin
proteins. Trends Biochem. Sci. 28 (2), 106–112.
Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., Sodroski, J., 2004. The
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World
monkeys. Nature 427 (6977), 848–853.
Tanaka, M., Ueno, T., Nakahara, T., Sasaki, K., Ishimoto, A., Sakai, H., 2003. Down-
regulation of CD4 is required for maintenance of viral infectivity of HIV-1. Virology
311 (2), 316–325.
Ugolini, S., Mondor, I., Parren, P.W., Burton, D.R., Tilley, S.A., Klasse, P.J., Sattentau, Q.J.,
1997. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T
cell line-adapted HIV-1 neutralization. J. Exp. Med. 186 (8), 1287–1298.
Vodicka, M.A., Goh, W.C., Wu, L.I., Rogel, M.E., Bartz, S.R., Schweickart, V.L., Raport, C.J.,
Emerman, M., 1997. Indicator cell lines for detection of primary strains of human
and simian immunodeﬁciency viruses. Virology 233, 193–198.
von Lindern, J.J., Rojo, D., Grovit-Ferbas, K., Yeramian, C., Deng, C., Herbein, G., Ferguson,
M.R., Pappas, T.C., Decker, J.M., Singh, A., Collman, R.G., O'Brien, W.A., 2003.
Potential role for CD63 in CCR5-mediated human immunodeﬁciency virus type 1
infection of macrophages. J. Virol. 77 (6), 3624–3633.
von Schwedler, U.K., Stuchell, M., Müller, B., Ward, D.M., Chung, H.Y., Morita, E., Wang,
H.E., Davis, T., He, G.P., Cimbora, D.M., Scott, A., Kräusslich, H.G., Kaplan, J., Morham,
S.G., Sundquist, W.I., 2003. The protein network of HIV budding. Cell 114 (6),
701–713.
Warrilow, D., Meredith, L., Davis, A., Burrell, C., Li, P., Morita, E., Wang, H.E., Harrich, D.,
2008. Cell factors stimulate human immunodeﬁciency virus type 1 reverse
transcription in vitro. J. Virol. 82 (3), 1425–1437.
Warrilow, D., Warren, K., Harrich, D., 2010. Strand transfer and elongation of HIV-1
reverse transcription is facilitated by cell factors in vitro. PLoS ONE 5 (10),
e13229.
Zack, J.A., Arrigo, S.J., Weitsman, S.R., Go, A.S., Haislip, A., Chen, I.S., 1990. HIV-1 entry
into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral
structure. Cell 61, 213–222.
